Physician profile
Kyle Matthew Struzyk
NPI 1487188157
$643.84
in general payments reported to CMS, 2019-2025
3 companies · $382 in 2025
The $382 reported for 2025 was more than what 92% of Pediatric Anesthesiology providers received nationally (typical 2025 total: $40.62).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $22.86 · 2024: $239 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $543.03 | 2024-2025 | Invos |
| Atricure, INC. | $57.23 | 2025 | Synergy Ablation System |
| Merck Sharp & Dohme LLC | $43.58 | 2023-2024 | Bridion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Struzyk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.